These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35952318)

  • 41. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
    Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
    Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
    Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
    BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
    Ichihara E; Westover D; Meador CB; Yan Y; Bauer JA; Lu P; Ye F; Kulick A; de Stanchina E; McEwen R; Ladanyi M; Cross D; Pao W; Lovly CM
    Cancer Res; 2017 Jun; 77(11):2990-3000. PubMed ID: 28416483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
    Yano S; Takeuchi S; Nakagawa T; Yamada T
    Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
    Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
    Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
    Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M
    J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
    Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
    Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer.
    Wang Y; Zhang Y; Chen R; Tian X
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01047. PubMed ID: 36583451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient.
    Hu Y; Xiao L; Yang N; Zhang Y
    Thorac Cancer; 2019 May; 10(5):1252-1255. PubMed ID: 30788907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
    Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
    Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.